[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1114307T1 - Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν - Google Patents

Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν

Info

Publication number
CY1114307T1
CY1114307T1 CY20131100486T CY131100486T CY1114307T1 CY 1114307 T1 CY1114307 T1 CY 1114307T1 CY 20131100486 T CY20131100486 T CY 20131100486T CY 131100486 T CY131100486 T CY 131100486T CY 1114307 T1 CY1114307 T1 CY 1114307T1
Authority
CY
Cyprus
Prior art keywords
aquorin
compositions containing
methods used
methods
preventing
Prior art date
Application number
CY20131100486T
Other languages
English (en)
Inventor
Mark Y Underwood
Original Assignee
Quincy Bioscience, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience, Llc filed Critical Quincy Bioscience, Llc
Publication of CY1114307T1 publication Critical patent/CY1114307T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)

Abstract

Με την παρούσα εφεύρεση παρέχονται συνθέσεις που περιέχουν αικουορίνη και μέθοδοι για την χρήση τους στην πρόληψη ή και την ελάφρυνση συμπτωμάτων και διαταραχών που σχετίζονται με ανισορροπία ασβεστίου.
CY20131100486T 2004-06-21 2013-06-14 Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν CY1114307T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/872,795 US20060229243A1 (en) 2004-06-21 2004-06-21 Aequorin-containing compositions and methods of using same
EP05766584.6A EP1768691B1 (en) 2004-06-21 2005-06-21 Aequorin-containing compositions and methods of using same

Publications (1)

Publication Number Publication Date
CY1114307T1 true CY1114307T1 (el) 2016-08-31

Family

ID=35785748

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100486T CY1114307T1 (el) 2004-06-21 2013-06-14 Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν

Country Status (21)

Country Link
US (3) US20060229243A1 (el)
EP (2) EP1768691B1 (el)
JP (1) JP4971150B2 (el)
KR (1) KR101213555B1 (el)
CN (1) CN1997383B (el)
AU (1) AU2005265266B2 (el)
BR (1) BRPI0512392B1 (el)
CA (1) CA2571542C (el)
CY (1) CY1114307T1 (el)
DK (1) DK1768691T3 (el)
ES (1) ES2422173T3 (el)
HK (1) HK1109576A1 (el)
IL (1) IL180195A (el)
MX (1) MXPA06015037A (el)
NZ (1) NZ552274A (el)
PL (1) PL1768691T3 (el)
PT (1) PT1768691E (el)
SG (1) SG153848A1 (el)
SI (1) SI1768691T1 (el)
WO (1) WO2006010004A2 (el)
ZA (1) ZA200610688B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0625678D0 (en) 2006-12-21 2007-01-31 Lux Biotechnology Ltd Composition and method for detection of demineralisation
AU2009223010B2 (en) * 2008-03-11 2014-01-09 Quincy Bioscience, Llc. Apoaequorin-containing compositions and methods of using same
JP2010143860A (ja) * 2008-12-19 2010-07-01 Chisso Corp タンパク質の安定化剤
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
ES2687050T3 (es) * 2010-12-24 2018-10-23 Otsuka Pharmaceutical Co., Ltd. Método de bioensayo para la detección de sustancia fisiológicamente activa
LT2780027T (lt) * 2011-11-15 2017-10-25 Quincy Bioscience Llc Apoekvorinas, skirtas sumažinti neuronų pažeidimą dėl išemijos
GB201700317D0 (en) 2017-01-09 2017-02-22 Calcivis Ltd Detection device
USD1042180S1 (en) 2020-05-28 2024-09-17 Calcivis Limited Dental detection device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001240855A (ja) * 2000-03-01 2001-09-04 Masashi Sugimoto 生物発光方法及び発光物品
US6800492B2 (en) * 2000-06-01 2004-10-05 Institute Pasteur Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level
US6930169B2 (en) * 2000-06-12 2005-08-16 University Of Baltimore Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same

Also Published As

Publication number Publication date
HK1109576A1 (en) 2008-06-13
IL180195A0 (en) 2007-06-03
PL1768691T3 (pl) 2013-09-30
BRPI0512392B1 (pt) 2022-12-13
SG153848A1 (en) 2009-07-29
WO2006010004A3 (en) 2007-03-08
EP1768691A2 (en) 2007-04-04
DK1768691T3 (da) 2013-07-01
EP1768691A4 (en) 2010-08-04
EP1768691B1 (en) 2013-05-22
US7671015B2 (en) 2010-03-02
EP2545934A1 (en) 2013-01-16
JP4971150B2 (ja) 2012-07-11
US20100152117A1 (en) 2010-06-17
CA2571542C (en) 2014-08-19
KR20070070154A (ko) 2007-07-03
WO2006010004A2 (en) 2006-01-26
JP2008503581A (ja) 2008-02-07
AU2005265266B2 (en) 2011-05-12
IL180195A (en) 2014-03-31
PT1768691E (pt) 2013-06-20
ZA200610688B (en) 2007-12-27
KR101213555B1 (ko) 2012-12-18
US20060229243A1 (en) 2006-10-12
SI1768691T1 (sl) 2013-07-31
CN1997383B (zh) 2011-01-05
ES2422173T3 (es) 2013-09-09
CN1997383A (zh) 2007-07-11
MXPA06015037A (es) 2007-07-11
BRPI0512392A (pt) 2008-03-11
NZ552274A (en) 2010-06-25
CA2571542A1 (en) 2006-01-26
AU2005265266A1 (en) 2006-01-26
EP2545934B1 (en) 2014-12-10
US20080287350A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
CY1114307T1 (el) Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
CY1116169T1 (el) Συνθεσεις και μεθοδοι χρησης πεπτιδιων προνησιδιων και αναλογων εξ' αυτων
CR9428A (es) Metodos para el tratamiento y la prevencion de fibrosis
CY1116779T1 (el) Αμιδο ενωσεις και η χρηση τους ως φαρμακευτικες ουσιες
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
CR8766A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
MX2009013199A (es) Anticuerpos anti-notch1 nnr y sus metodos de uso.
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
DE602004005897D1 (de) Verpackte orthodontische anordnung mit klebenden vorbeschichteten geräten
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
BR0307017A (pt) agentes hipnóticos sedativos de ação rápida para anestesia e sedação
CY1114366T1 (el) Συνθεσεις που περιεχουν αποαικoυορiνη και μεθοδοι χρησης τους
SE0301650D0 (sv) Novel compounds
CY1114497T1 (el) ΜΕΘΟΔΟΙ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΙ ΤΗΝ ΠΡΟΛΗΨΗ ΝΟΣΟΥ ΠΟΥ ΣΧΕΤΙΖΕΤΑΙ ΜΕ ΤΗΝ ΙΝΤΕΓΚΡΙΝΗ ανβ5
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
CY1111007T1 (el) Νεος συνδυασμος ενος αναστολεα του φλεβοκομβικου ρευματος if και ενος αναστολεα ασβεστιου και φαρμακευτικες συνθεσεις που τον περιεχουν